## Nahdi Medical Co. (NAHDI)

## 3Q2023 First Look


| Profitability Decre  | November 1, 2023 |                        |       |                                       |       |                                 |
|--|------------------|------------------------|-------|---------------------------------------|-------|---------------------------------|
| Upside to Target Price<br>Expected Dividend Yield<br>Expected Total Return |                  | 50.9%<br>2.1%<br>53.0% |       | Rating<br>Last Price<br>12-mth target |       | Buy<br>SAR 141.80<br>SAR 214.00 |
| NAHDI  | 3Q2023           | 3Q2022                 | Y/Y   | 2Q2023                                | Q/Q   | <b>RC Estimate</b>              |
| Sales  | 2,163            | 2,159                  | 0%    | 2,231                                 | (3%)  | 2,188                           |
| Gross Profit   | 874              | 911                    | (4%)  | 896                                   | (2%)  | 923                             |
| Gross Margins  | 40%              | 42%                    |       | 40%                                   |       | 41%                             |
| Operating Profit   | 230              | 279                    | (17%) | 283                                   | (19%) | 306                             |
| Net Profit   | 213              | 254                    | (16%) | 265                                   | (20%) | 273                             |

(All figures are in SAR mln)

- NAHDI record revenues of SAR 2.2 bln, in-line with our estimates, a result which was flat Y/Y but lower -3% Q/Q. This slight decrease Q/Q was expected, considering seasonality. However, the extent to which the gross margins contracted was unanticipated, with decreases of -100 bps Q/Q and -200 bps Y/Y. Gross profit also came in lower, at SAR 874 mln, a decrease of -2% Q/Q and -4% Y/Y, respectively. Management stated that declines in gross profit and gross margin were a result of increases in promotional spending, which would have an adverse effect on COGS.
- NAHDI posted a net profit for the quarter of SAR 213 million, a decline of -16% Y/Y, but also -20% Q/Q, which is a stark contrast, given that according to management, this was actually offset by returns generated from deposits. This material decline Y/Y was driven by increases in operating expenses, which are tied to growth related initiatives. NAHDI experienced similar decreases in operating profitability, which came in at of SAR 230 million; a decline of -17% Y/Y. Declines in this metric were a result of lower gross margins and self-funded investments in other aspects of the business, such as the healthcare business, clinics, and the continued digital transformation of NAHDI.
- For 1H2023, NAHDI declared a cash dividend of SAR 2.50 per share. Given the current capital position of the Company, a rising interest rate environment, and its top position in its given market, we believe these distributions will be well covered and continue. Thus, we maintain our target price of SAR 214.00 and Buy rating.



| Market Data        |                   |  |  |
|--------------------|-------------------|--|--|
| 52-week high/low   | SAR 204.8 / 135.0 |  |  |
| Market Cap         | SAR 18,434 mln    |  |  |
| Shares Outstanding | 130 mln           |  |  |
| Free-float         | 30%               |  |  |
| 12-month ADTV      | 229,228           |  |  |
| Bloomberg Code     | NAHDI AB          |  |  |



■NAHDI ■TASI

Brennan Eatough brennan.eatough@riyadcapital.com +966-11-203-6808

## Stock Rating

| Buy  | Neutral  | Sell                                 | Not Rated                |
|--|--|--------------------------------------|--------------------------|
| Expected Total Return<br>Greater than +15% | Expected Total Return<br>between -15% and +15% | Expected Total Return less than -15% | Under Review/ Restricted |

The expected percentage returns are indicative, stock recommendations also incorporate relevant qualitative factors For any feedback on our reports, please contact research@riyadcapital.com

Riyad Capital is a Saudi Closed Joint Stock Company with Paid up capital of SR 500 million, licensed by the Saudi Arabian Capital Market Authority NO.07070-37. Commercial Registration No: 1010239234. Head Office: Granada Business Park 2414 AI-Shohda Dist. – Unit No 69, Riyadh 13241 - 7279 Saudi Arabia. Ph: 920012299. The information in this report was compiled in good faith from various public sources believed to be reliable. Whilst all reasonable care has been taken to ensure that the facts stated in this report are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable. Rivad Capital makes no representations or warranties whatsoever as to the accuracy of the data and information provided and, in particular, Riyad Capital does not represent that the information in this report is complete or free from any error. This report is not, and is not to be construed as, an offer to sell or solicitation of an offer to buy any financial securities. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this report. Rivad Capital accepts no liability whatsoever for any loss arising from any use of this report or its contents, and neither Rivad Capital nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof. Riyad Capital or its employees or any of its affiliates or clients may have a financial interest in securities or other assets referred to in this report. Opinions, forecasts or projections contained in this report represent Riyad Capital's current opinions or judgment as at the date of this report only and are therefore subject to change without notice. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections which represent only one possible outcome. Further, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified and future actual results or events could differ materially. The value of, or income from, any investments referred to in this report may fluctuate and/or be affected by changes. Past performance is not necessarily an indicative of future performance. Accordingly, investors may receive back less than originally invested amount. This report provides information of a general nature and does not address the circumstances, objectives, and risk tolerance of any particular investor. Therefore, it is not intended to provide personal investment advice and does not take into account the reader's financial situation or any specific investment objectives or particular needs which the reader may have. Before making an investment decision the reader should seek advice from an independent financial, legal, tax and/or other required advisers due to the investment in such kind of securities may not be suitable for all recipients. This research report might not be reproduced, nor distributed in whole or in part, and all information, opinions, forecasts and projections contained in it are protected by the copyright rules and regulations.

